Methods : Pts (n = 56) were assigned by histology to receive N 10mg/kg IV Q3W + concurrent IV gemcitabine 1250mg/m 2 + cisplatin 75mg/m 2 (squamous [sq]) or pemetrexed 500mg/m 2 + cisplatin 75mg/m 2 (non-sq), or
phase 3 randomized studies will explore these markers and other phenotypic changes in immune cell populations that might predict activity of Nivo in patients with MEL and other advanced cancers.Michael A Postow*Diana M CardonaJanis M TaubeRobert A Anders...